Catalyst Pharmaceutical Partners Reports Dismissal of Stockholder Class Action Lawsuit

Catalyst Pharmaceutical Partners Reports Dismissal of Stockholder Class Action
Lawsuit

CORAL GABLES, Fla., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company
focused on developing safe and effective, approved medicines targeting orphan
neuromuscular and neurological diseases, today announced that on January 3,
2014, the previously reported stockholder class action lawsuit that had been
filed against Catalyst and certain of its officers and directors was dismissed
without prejudice. In the Court's order, the plaintiffs were granted leave to
file an amended complaint within 20 days. Catalyst has no information as to
whether any such amended complaint is planned by the plaintiffs. If an amended
complaint is filed in the case, Catalyst intends to vigorously defend the
amended lawsuit.

In October and November 2013, three securities class action lawsuits were
filed against Catalyst and certain of its officers and directors in the U.S.
District Court for the Southern District of Florida. The complaints, which
were substantially identical, purported to state a claim for violation of
federal securities laws on behalf of a class of those who purchased Catalyst's
common stock between October31, 2012 and October18, 2013. Two of the
lawsuits were voluntarily dismissed by the plaintiffs, and the last remaining
case was the case dismissed on Friday.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal Phase 3 trial
and recently received Breakthrough Therapy Designation from the U.S. Food and
Drug Administration (FDA). In 2012, Catalyst licensed Firdapse from BioMarin
and Catalyst assumed management of the Phase 3 pivotal trial initiated by
BioMarin. Firdapse is the first and only European approved drug for
symptomatic treatment in adults with LEMS.

Catalyst is also developing a potentially safer and more potent vigabatrin
analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well
as other neurological conditions associated with reduced GABAergic signaling,
like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been
granted U.S. orphan drug designation for the treatment of infantile spasms by
the FDA and has been granted E.U. orphan medicinal product designation for the
treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase 3 trial of Firdapse™, whether the Phase 3
trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse will expedite the development and review of Firdapse
by the FDA, whether an NDA for Firdapse will ever be accepted for filing by
the FDA, the timing of any such NDA filing or acceptance, whether Catalyst
will be the first company to receive an approval for 3,4-DAP, giving it 7-year
marketing exclusivity for its product, whether any of Catalyst's product
candidates will ever be approved for commercialization or successfully
commercialized, whether the class action lawsuit will be refiled and the
ultimate outcome of that lawsuit, and those other factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2012 and other
filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: Media/Investor Contacts
         Donna LaVoie or David Connolly
         LaVoie Group
         (617) 374-8800
         dlavoie@lavoiegroup.com
         dconnolly@lavoiegroup.com
        
         Company Contact
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners, Inc.
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
 
Press spacebar to pause and continue. Press esc to stop.